FGFR3 and urinary bladder carcinoma: FGFR3 inhibitors have shown anti-tumor cell proliferation and pro-apoptotic effects on bladder cancer cells carrying FGFR3 gene mutations, indicating that the status of FGFR3 gene mutations can predict patients’ response to targeted therapy.